Germany is seen as the jewel of the European crown for many operators within the cannabis industry. This is not surprising given that Germany has the largest population in the European Union, its citizens are relatively affluent, it boasts a solid infrastructure and, most importantly, it has a functioning medicinal cannabis programme.
A characteristic, if not stereotype, of the Germans is an exacting attention to detail. This permeates society on many levels. It’s no surprise then that to grow medicinal cannabis in Germany, the bar is set high. In fact, it is set so high, domestic supply is limited and it is unlikely to produce enough to satisfy the German market any time soon. This offers a wonderful opportunity for medicinal cannabis cultivators based in other countries.
In order to supply medicinal cannabis to the ever-growing medical market, German pharmacies need to rely on imported products. As the number of markets in which it is legal to grow medicinal cannabis is limited, this offers a huge opportunity for countries such as Canada, who are able to export.
Opportunities also lie for German distributors who hold the necessary licenses to import, store and distribute cannabis-based medicinal products into German pharmacies. One such company is Cansativa GmbH.
To import and distribute medicinal cannabis you need a plethora of licenses, “A GMP and GDP certified importer in Germany needs to hold a Manufacturing and Importation Authorization (MIA) according to Sec. 13, 72 AMG. As opposed to a Wholesale Distribution Authorization (WDA) according to Sec. 52a AMG and finally a licence for the trade in narcotic drugs Sec. 3 BtMG.” Explains Benedikt Sons, CEO and Co-Founder of Cansativa.
“Most of the German ‘so called importers’ do not hold a Manufacturing and Import authorization without which you are not GMP. Cansativa hold all necessary licences. If an importer wants to import products from a non-EU country, for example Canada, a Manufacturing and Importation Authorization (MIA) according to Sec. 13, 72 AMG is required as they will bring the products to market as the legal manufacturer.”
Cansativa are connected to every pharmacy in Germany, who surprisingly make around 60% of their orders using a fax machine.
“Our company philosophy is to globally source the best quality cannabis products at the lowest prices,” says Jakob Sons, General Counsel and Co-Founder of Cansativa. “Our market has already tripled since we launched in 2017 and we expect continued growth as the German market matures.”
The German market relies on imports from Canada, Netherlands and further countries. The estimated full year German market size 2019 is 5.5 tonnes of medicinal cannabis.
Cansativa’s partnerships do not stop at the raw product itself. They also have a deal with the US-based vaporizer company DaVinci, who is moving into the medical market. Cansativa Medical Devices GmbH, a subsidiary of Cansativa GmbH, develops and manufactures medical devices in cooperation with DaVinci.
Cansativa are truly an example of transatlantic cannabis partnerships in action.
Cansativa CEO, Benedikt Sons will be at the upcoming Cannabis Europa event in NYC on November 7th and will be discussing their experience in fostering global partnerships to serve the German patients.
Secure your tickets now: https://www.cannabis-europa.com/buy-ticket/